Subject(s)
Anilides/administration & dosage , Antineoplastic Agents/administration & dosage , Carcinoma, Basal Cell/drug therapy , Chemical and Drug Induced Liver Injury/prevention & control , Eyelid Neoplasms/drug therapy , Pyridines/administration & dosage , Skin Neoplasms/drug therapy , Aged , Anilides/adverse effects , Antineoplastic Agents/adverse effects , Chemical and Drug Induced Liver Injury/etiology , Humans , Male , Pyridines/adverse effectsSubject(s)
Coronavirus Infections/epidemiology , Pandemics/statistics & numerical data , Pneumonia, Viral/epidemiology , Urticaria/pathology , Vasculitis, Leukocytoclastic, Cutaneous/epidemiology , Vasculitis, Leukocytoclastic, Cutaneous/pathology , Aged , Biopsy, Needle , COVID-19 , Comorbidity , Coronavirus Infections/diagnosis , Female , Humans , Immunohistochemistry , Incidence , Male , Middle Aged , Pneumonia, Viral/diagnosis , Prognosis , Risk Assessment , Sampling Studies , Severity of Illness Index , Urticaria/diagnosis , Urticaria/epidemiologyABSTRACT
COVID-19 is an infectious disease caused by severe acute respiratory coronavirus 2 (SARS-CoV-2). Vesicular skin rashes have been reported as associated with COVID-19, but there is little information about this cutaneous manifestation. We designed a prospective observational study of patients diagnosed with COVID-19 who had vesicular lesions. Clinical characterization of skin findings was conducted by dermatologists. When possible, histological analysis and detection of SARS-CoV-2 in the content of the vesicles was performed. In total, 24 patients were included. A disseminated pattern was found in 18 patients (75%), and a localized pattern was found in 6 (25%). Median duration of the skin rash was 10 days. Of the 24 patients, 19 (79.2%) developed the skin rash after the onset of COVID-19 symptoms. Histological examination in two patients was consistent with viral infection, SARS-CoV-2 was not detected in four patients. This single-centre study shows the clinical characteristics of vesicular skin rashes in patients with COVID-19.
Subject(s)
Blister/virology , COVID-19/complications , Exanthema/virology , Adult , Aged , Blister/pathology , Exanthema/pathology , Female , Humans , Male , Middle Aged , Prospective Studies , SARS-CoV-2/isolation & purification , Young AdultABSTRACT
INTRODUCTION: Dermatological complaints have been estimated to represent up to 5-10% of all the visits to emergency departments. The main objective of our study was to determine how affected is the Health related Quality of Life (HRQL) in a series of patients attending an emergency department due to skin symptoms. PATIENTS AND METHODS: A prospective study during one month (July 2016) was conducted in a hospital with full-time on-call dermatologists. The Short-Form SF-12v2 Health Survey and the Dermatology Life Quality Index (DLQI) were offered to all the patients over 18 years old attending the emergency department with cutaneous complaints. Clinical and epidemiological characteristics were also collected. RESULTS: In total 108 patients completed the study. Mean age found was 45.1±16.1 years. Mean DLQI score found was 10.56±6.12. Fifty-three patients (49%) had a score of 11 or higher in the DLQI questionnaire. Most affected subscales were "Symptoms and Feelings" in DLQI scale and "Overall Health" and "Vitality" for the SF-12. A very significant difference (p<0.0001) was found between women's (12.4±5.7) and men's (7.5±5.6) DLQI mean score (mean difference of 4.9; 95% confidence interval of the difference: 2.7-7.1). CONCLUSIONS: Patients visiting emergency units with cutaneous complaints seem to feel a moderate-large impact on their quality of life which is mainly related to the symptoms and feelings that they are experiencing. This impact is significantly higher among women.
